Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

Stephen D Wiviott, Marcus D Flather, Michelle L O'Donoghue, Shinya Goto, Desmond J Fitzgerald, Fernando Cura, Philip Aylward, Victor Guetta, Dariusz Dudek, Charles F Contant, Dominick J Angiolillo, Deepak L Bhatt, LANCELOT-CAD Investigators

Research output: Contribution to journalArticlepeer-review


Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.
Original languageEnglish
Pages (from-to)1854-63
Number of pages10
Issue number17
Publication statusPublished - 3 May 2011


  • Aged
  • Biological Markers
  • Blood Platelets
  • Coronary Artery Disease
  • Dose-Response Relationship, Drug
  • Female
  • Hemorrhage
  • Humans
  • Imines
  • Male
  • Middle Aged
  • Platelet Activation
  • Platelet Aggregation Inhibitors
  • Pyridines
  • Receptors, Thrombin

Cite this